C4 Therapeutics (CCCC) Price & Analysis

Compare

499 Followers

CCCC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.09 - $7.66

Previous CloseN/A

Volume165.25K

Average Volume (3M)930.70K

Market Cap

$122.84M

Enterprise Value$114.64M

Total Cash (Recent Filing)$244.90M

Total Debt (Recent Filing)$65.76M

Price to Earnings (P/E)―

Beta3.36

Next Earnings

Aug 06, 2025

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding71,007,080

10 Day Avg. Volume844,458

30 Day Avg. Volume930,698

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)0.48

Price to Sales (P/S)0.00

P/FCF Ratio-1.60

Enterprise Value/Market Cap0.93

Enterprise Value/Revenue0.97

Enterprise Value/Gross Profit4.14

Enterprise Value/Ebitda-0.28

Forecast

1Y Price Target

$3.50

Price Target Upside108.33% Upside

Rating ConsensusHold

Number of Analyst Covering0

C4 Therapeutics News

PremiumCompany Announcements

C4 Therapeutics Reports Q1 2025 Financial Results

1M ago

CCCC

PremiumCompany Announcements

C4 Therapeutics Updates on Cemsidomide Clinical Trial

1M ago

CCCC

PremiumThe Fly

C4 Therapeutics reports Q1 EPS (37c), consensus (42c)

1M ago

CCCC

PremiumCompany Announcements

C4 Therapeutics Board Member Bruce Downey Retires

2M ago

CCCC

PremiumRatings

C4 Therapeutics: Promising Clinical Developments and Strategic Plans Justify Buy Rating

3M ago

CCCC

PremiumCompany Announcements

C4 Therapeutics Reports Strong 2024 Financial Performance and Clinical Progress

3M ago

CCCC

PremiumThe Fly

C4 Therapeutics reports Q4 EPS (49c), consensus (45c)

3M ago

CCCC

PremiumThe Fly

C4 Therapeutics sees cash runway into 2027

3M ago

CCCC

See All CCCC News

See All News >

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.

Partnership PotentialManagement intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.

Product DevelopmentCFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.

Bears Say

Safety ConcernsThere were notable Grade 3 or higher treatment-related adverse events, such as neutropenia and anemia.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

3.13% Insiders

15.09% Mutual Funds

54.06% Other Institutional Investors

17.97% Public Companies and Individual Investors

Detailed Ownership Overview >

CCCC FAQ

What was C4 Therapeutics’s price range in the past 12 months?

C4 Therapeutics lowest stock price was $1.08 and its highest was $7.66 in the past 12 months.

What is C4 Therapeutics’s market cap?

C4 Therapeutics’s market cap is $122.84M.

When is C4 Therapeutics’s upcoming earnings report date?

C4 Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 56 days.

How were C4 Therapeutics’s earnings last quarter?

C4 Therapeutics released its earnings results on May 07, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.442 by $0.072.

Is C4 Therapeutics overvalued?

According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does C4 Therapeutics pay dividends?

C4 Therapeutics does not currently pay dividends.

What is C4 Therapeutics’s EPS estimate?

C4 Therapeutics’s EPS estimate is -0.4.

How many shares outstanding does C4 Therapeutics have?

C4 Therapeutics has 71,007,080 shares outstanding.

What happened to C4 Therapeutics’s price movement after its last earnings report?

C4 Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.442. Following the earnings report the stock price went up 6.383%.

Which hedge fund is a major shareholder of C4 Therapeutics?

Currently, no hedge funds are holding shares in CCCC

C4 Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-45.55%

Trailing 12-Months

Asset Growth

-19.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

C4 Therapeutics

C4 Therapeutics (CCCC) is a biotechnology company focused on pioneering a new class of targeted protein degradation (TPD) medicines to treat cancer and other diseases. Operating within the biopharmaceutical sector, the company utilizes its proprietary technology platform, TORPEDO, to develop small-molecule drugs that selectively degrade disease-causing proteins. By harnessing the body's natural protein disposal system, C4 Therapeutics aims to address challenging targets that have been deemed undruggable by traditional approaches.

CCCC Stock 12 Month Forecast

Average Price Target

$3.50

▲(108.33%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,1.7738461538461539,1.9176923076923076,2.0615384615384613,2.2053846153846153,2.3492307692307692,2.4930769230769227,2.6369230769230767,2.7807692307692307,2.9246153846153846,3.0684615384615386,3.212307692307692,3.356153846153846,{"y":3.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,1.7738461538461539,1.9176923076923076,2.0615384615384613,2.2053846153846153,2.3492307692307692,2.4930769230769227,2.6369230769230767,2.7807692307692307,2.9246153846153846,3.0684615384615386,3.212307692307692,3.356153846153846,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.63,1.7738461538461539,1.9176923076923076,2.0615384615384613,2.2053846153846153,2.3492307692307692,2.4930769230769227,2.6369230769230767,2.7807692307692307,2.9246153846153846,3.0684615384615386,3.212307692307692,3.356153846153846,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.52,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.78,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >